• Unlocking regenerative healing for everybody
• World-leading outcomes, unmatched value, and widespread impact
• Positive EBITDA and strong cash position

Aroa Biosurgery Ltd, a world-leading soft tissue regeneration company, reported its FY25 full year results. The company achieved total revenue of NZ$84.7m, representing a 23% year-over-year growth, and normalised EBITDA of NZ$4.2m, a significant improvement from the previous year. Aroa's product gross margin remained strong at 86%. The company saw growth across its product portfolios, with Myriad sales growing 24% year-over-year, Symphony sales increasing 35%, and Endoform sales remaining stable. Aroa's partnership with TELA Bio also contributed to the revenue growth, with their shared Ovitex product line. The company's cash balance at the end of the period was NZ$22.0m, providing a solid financial position to support future growth initiatives. Aroa's strategic focus remains on improving healing rates and decreasing complications across its three key product areas: complex wounds, soft tissue reconstruction, and chronic wounds. The company is pursuing adjacent opportunities in areas such as suture line reinforcement, women's health, and craniomaxillofacial applications. Looking ahead, Aroa provided FY26 guidance of NZ$92-100m in total revenue, representing 10-20% year-over-year growth on a constant currency basis, and NZ$5-8m in normalised EBITDA.

For FY26, Aroa provided guidance of NZ$92-100m in total revenue, representing 10-20% year-over-year growth on a constant currency basis, and NZ$5-8m in normalised EBITDA.

Aroa's strategic focus remains on improving healing rates and decreasing complications across its three key product areas: complex wounds, soft tissue reconstruction, and chronic wounds. The company is pursuing adjacent opportunities in areas such as suture line reinforcement, women's health, and craniomaxillofacial applications. Key milestones for FY26 include securing Symphony reimbursement in physician offices, completing the Symphony randomized controlled trial, and demonstrating Myriad's distinctive value through deeper account penetration, faster sales ramp, and increased productivity.